Biopharma and Medtech Activity in Q2 2026

Biopharma and medtech activity in Q2 2026

The latest J.P. Morgan deal reports, powered by DealForma, analyze Q2 2026 licensing, M&A, venture funding, and IPO activity, highlighting the trends shaping the biopharma and medtech industries.

Download the Biopharma and Medtech reports

DealForma Research

Explore More
Biopharma Therapeutics and Platforms M&A - Q2 2026 Review

Biopharma Therapeutics and Platforms M&A – Q2 2026 Review

Biopharma Therapeutics and Platforms R&D Partnerships - Q2 2026 Review

Biopharma Therapeutics and Platforms R&D Partnerships – Q2 2026 Review

global healthcare and life sciences

Global Healthcare and Life Sciences – Q2 2026 Review

All of this by stage, disease indication, modality, target…

Schedule your Demo
+ 0 k
Licensing Deals
+ 0 k
M&A
+ 0 k
Other Deals
+ 0 k
Funding Rounds
+ 0 k
Company Profiles
+ 0 k
Drug Sales Figures
DealForma Logo

DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.

Linkedin

Database

Company

Comparisons

Website Design by Once Interactive